May 20, 2013
J.K. WallThe study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare
to pay for use of its brain imaging agent Amyvid.
More
May 16, 2013
Bloomberg NewsEli Lilly claims recent decisions by Canadian courts invalidating 17 drug patents have made the country an outlier among major
developed countries.
More
May 10, 2013
Bloomberg NewsThe drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual
sales by 2018.
More
May 6, 2013
J.K. WallLilly will eliminate 1,624 positions from its U.S. sales force in July, according to a notice the company made to state officials.
But some of those workers may be rehired by the firm.
More
May 6, 2013
Associated PressMajor drugmakers, including Indianapolis-based Eli Lilly and Co., are closely watching Pfizer Inc.'s plan to sell Viagra directly
to consumers. The bold move blows up the drug industry's distribution model.
More
April 25, 2013
Bloomberg NewsEli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay
availability of a potential treatment for Alzheimer’s disease.
More
April 23, 2013
Associated PressA pharmacy that makes specialty medications is recalling nearly 100 compounded drugs after federal regulators found potential
safety problems during an inspection.
More
April 22, 2013
J.K. WallInvestors are gaining confidence in the ability of major drugmakers, including Eli Lilly and Co., to improve their pipelines
of new products. The big pharma firms begin to report first-quarter earnings this week.
More
April 18, 2013
IBJ StaffThe pharmaceutical firm has $400 million in projects in the works for its facilities south of downtown. City officials have
advanced its request for tax breaks to a public hearing and final consideration May 1.
More
April 15, 2013
Mason KingIndianapolis development officials on Wednesday will weigh the 10-year requests from the pharmaceuticals giant related to
a new manufacturing plant and improvements to existing operations downtown.
More
April 11, 2013
J.K. WallThe Indianapolis pharmaceuticals giant said Thursday that it would lay off hundreds of U.S. sales reps, as it prepares for
the loss of patent protection on two of its best-selling drugs.
More
March 31, 2013
Bloomberg NewsJohnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family
of diabetes drugs, giving them the edge against rivals including Eli Lilly and Co. that are developing similar medicines.
More
March 25, 2013
Associated PressEli Lilly and Co. said Monday that it has submitted a new type 2 diabetes treatment it is developing with German drugmaker
Boehringer Ingelheim to the Food and Drug Administration.
More
March 25, 2013
Associated PressConsumers would face tighter limits on the quantities they could buy of cold and allergy pills often used to make methamphetamine
under a proposal approved by Indiana lawmakers.
More
March 25, 2013
Associated PressFederal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors
to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for
years, steep price declines.
More
March 12, 2013
Associated PressMore than two dozen of the world's largest pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., have
agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs.
More
March 2, 2013
Bloomberg NewsEli Lilly and Co. has sued Roche Holding AG’s Genentech unit, asking a court to invalidate patents used to make treatments
for cancer and autoimmune diseases.
More
February 26, 2013
J.K. WallEndocyte Inc. saw its shares fall nearly 7 percent Tuesday morning after the drug development firm announced that its application
for U.S. approval of a cancer drug could be delayed another 10 months.
More
February 14, 2013
IBJ Staff and Associated PressDiagnostic products maker Qiagen NV said Wednesday that it will work with Eli Lilly and Co. to develop new tests that could
identify patients who could be helped by Lilly's drugs.
More
February 7, 2013
Bloomberg NewsEli Lilly said it is halting testing of experimental drug tabalumab because the studies show the medicine is not effective.
The company said it expects to take a $50 million charge in the first quarter related to the research expenses from the drug.
More
February 7, 2013
IBJ StaffElona Biotechnologies Inc., which has been struggling to repay Greenwood for more than $8 million in economic development
incentives, says it has solution to its financial problems.
More
February 4, 2013
J.K. WallWith Eli Lilly and Co. set to see patents expire on its best-selling drug at year’s end, it is in the company’s
interest to say its pipeline is about to produce new drugs. But the Indianapolis drugmaker may be in a position to submit
five new drugs for regulatory approval this year.
More
February 2, 2013
Hall Render Killian Heath & Lyman will draw on existing expertise within the firm to create the 10-member group.
More
January 26, 2013
J.K. WallTwo years ago, executives at AIT Laboratories “took their eye off the ball,” and watched the company’s business
plummet 29 percent in value. Now, after two years of turmoil, the drug-testing lab says it’s poised to return to the
double-digit rates of growth that made it a local star.
More
January 22, 2013
J.K. WallGreenwood-based Elona Biotechnologies Inc., which has been trying to bring a generic version of insulin to market, was declared
in default on $8.4 million in incentives from the city of Greenwood.
More
Steak and Shake USED to be a good place to eat, but the now empty parking spaces tell the story of Poor Service, Declining quality of food and just more gimmicks and rear cooking....I used to be a customer, but no more...won't be back...to many other Good Places to eat in INDY...
This man has continued to destroy the Steak and Shake brand. Did he not learn from the sins of owners past. The SNS logo and Brand are strong, I cant understand why he wants to destroy the brand other than to satisfy his big ego.This will turn out to be a big mistake. Sleek new look for a traditional product..makes no logical sense
I mean REALLY!!! What's next taking away the Burger King's crown, turn the golden arches into silver columns? No I know let's get Wendy a pink mohawk.
A couple of thoughts on some of the information presented here from someone with a bit of experience in this area: First, Does anyone remember a time in the past 35 years when insurance premiums DIDN'T increase? They increase every year. The more rigorous rate review requirements of the Affordable Care Act (effective in 2011) have likely caused those increases to moderate as they have averaged below 10% for the past few years, down from much higer averages in prior years. Second, Oregon will operate a state-based Exchange. Recently, they were one of the first states to release their proposed (not yet reviewed by regulators)premium rates -- our first view of Exchange rates. After 2 insurers saw their competitors' rates, they pulled theirs back and re-submitted LOWER rates. In my nearly 10 years as a state insurance regulator, and two years as a federal regulator, I don't ever recall an insurer voluntarily lowering its rates. THAT'S the kind of transparency and competition the online marketplaces (Exchanges) will bring about. 3) ...and this is just a random thought: A big concern among health policy experts is the capacity of the primary care provider community to handle the happy fact that a large number of individuals will be newly-insured under the Affordable Care Act. With the system being stretched so thin for INSURED individuals, It seems highly doubtful that more than a very few "cash-and-carry" physicians will be able to survive in the new, improved healthcare system. Sally McCarty Center on Health Insurance Reform Georgetown University Health Policy Institute
liek the rest of America